2012 Society of Surgical Oncology Cancer Symposium

Matthew Stenger / April 15 2012 / 2012 Society of Surgical Oncology Cancer Symposium

Neoadjuvant Aromatase Inhibitor Therapy Converts Many Patients to Candidates for Breast-conserving Surgery

The American College of Surgeons Oncology Group (ACOSOG) Z1031 trial examined the effect of neoadjuvant aromatase inhibitor therapy on clinical response and breast-conservation rates in postmenopausal...

Breast Cancer

Matthew Stenger / May 15 2012 / 2012 Society of Surgical Oncology Cancer Symposium

Inhibition of SFRP2 Found to Inhibit Growth of Triple-negative Breast Tumors

Secreted frizzled related protein 2 (SFRP2), a protein that modulates the Wnt signaling pathway and is involved in embryonic development, has been thought to exert a tumor-suppressive effect via inhib...

Hepatobiliary Cancer

Matthew Stenger / May 15 2012 / 2012 Society of Surgical Oncology Cancer Symposium

Regional Infusion of Designer T Cells to Treat Intrahepatic Metastases

Designer T cells are modified from normal T cells to express specific immune receptors that allow them, via antibody-directed recognition or other mechanisms, to kill malignant cells bearing particula...

Dec

Today In Oncology

2012 Society of Surgical Oncology Cancer Symposium

Neoadjuvant Aromatase Inhibitor Therapy Converts Many Patients to Candidates for Breast-conserving Surgery

Inhibition of SFRP2 Found to Inhibit Growth of Triple-negative Breast Tumors

Regional Infusion of Designer T Cells to Treat Intrahepatic Metastases

ASCO and Friends of Cancer Research Applaud NCI’s Expansion of Clinical Trial Eligibility Criteria

FDA Pipeline: New Priority Reviews, Designations, and Clearances, Plus Statements on Genetic Testing and Class Labeling

Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer and Misdiagnosis of MSI or dMMR Status

POEMS/SWOG Intergroup S0230 Study on Preventing Early Menopause

Vitamin D Supplementation and Cancer Risk

A Gleason 6 Tumor: Is It Cancer, and Should It Be Treated?

SABCS 2018: Does Adjuvant Capecitabine Improve Outcomes in Early-Stage Triple-Negative Breast Cancer?

FDA Approves Atezolizumab in Combination With Bevacizumab and Chemotherapy for First-Line Treatment of Metastatic, Nonsquamous NSCLC

SABCS 2018: Circulating Tumor Cell Count May Help Choose First-Line Treatment for Metastatic Breast Cancer

ASH 2018: Ibrutinib Plus Rituximab vs Standard Chemoimmunotherapy in Younger Patients With Treatment-Naive CLL

Tait D. Shanafelt, MD, on CLL: Results From a Trial of the ECOG-ACRIN Cancer Research Group

Francesca M. Gay, MD, on Multiple Myeloma: Results From the Forte Trial

Anas Younes, MD, on DLBCL: Phase III Trial Results

Andrew D. Seidman, MD, and Charles E. Geyer, MD, on HER2-Positive Breast Cancer: Results From the KATHERINE Trial

Julie Vose, MD, MBA, and Loretta J. Nastoupil, MD, on Large B-Cell Lymphoma: Real-World Experience With CAR T-Cell Therapy